1[1]Le Chevalier T. Gemcitabine and pemetrexed (Alimta) in thoracic cancers: Present and future perspectives. Introduction and current controversies. Semin Oncol, 2002, 29 (3 Suppl 9) :43
2[2]Ettinger, D S. Gemcitabine/Alimta in locally advanced or metastatic non small cell lung cancer. Oncology- (Huntingt), 2000,14 (7 Suppl 4 ) : 49
3[3]Frances A Shepherd, Janet Dancey, Rodryg Ramlau, et al.Prospective randomized trial of docetaxel versus best supportive care in patients with Non small cell lung cancer previously teated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10) :2095
4[4]Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 2003, 21:2636
5[5]Smit EF, Mattson K, Von Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase Ⅱ study. Ann Oncol, 2003, 14 (3) :455
6[6]Hanna NH, Shepherd F A, Rosell R, et al. A phase Ⅲ study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. ASCO Pro, 2003, 2503
7[7]Shepherd, F A. Second line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther, 2003, 3 (4) :435
8[8]Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 NonSmall Cell Lung Cancer Study Group. J Clin Oncol, 2000, 18:2354
9[9]Takeda K, Negoro S, Tamura T, et al. Docetaxel (D)versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104). 2004 ASCO, Proceeding 7034
10[10]Pectasides D, Farmakis D, Pectasides M, et al. Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase Ⅱ trial. 2004 ASCO, Proceeding 7033
4Hainsworth JD, Morrissery LH, Scullin DC Jr, et al. Paclitaxel,carboplatin and topotecan in the treatment of patients with small cell lung cancer: a phase Ⅱ trial of the Minnie Pearl Cancer Research Network [ J ] . Cancer, 2002, 94(9): 2426-2433.
5Giaccone G. Identification of new drugs in pretreated patients with small cell lung cancer [ J ] . Eur J Cancer Clin Oncol, 1989, 25(3): 411-413.
6Klasa R J, Meyer RM, Shusic C, et al. Randomized phase Ⅲ study of fludarabine phosphate versus cyclophosphamide, vincristine ,and prednisone in patients with recurrent low- grade non-Hodgkin's lymphoma previously treated with an alkyating agent or alkylator-containing regimen [ J ] . J Clin Oncol, 2002, 20(14): 4649-4654.
7O'Brien ME, Cinleanu TE, Tsekov H, et al. Phase m trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer [ J ]. J Clin Oncol, 2006, 24(34): 5441-5447.
8Ichiki M, Gohara R, Rikimaru T, et al . Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase Ⅱ study [ J ] . Chemotherapy, 2003, 49(4): 200-205.
9周际昌.实用肿瘤内科学[M].北京：人民卫生出版社,1997.72.
10Hainsworth JD,Morrissery LH,Scullin DC,et al.Paclitaxel,carboplatin and topotecan in the treatment of patients with small cell lung cancer:a phase Ⅱtrial of the Minnie Pearl Cancer Research Network[J].Cancer,2002,94(9):2426-2433.
